Horizon Therapeutics to Expand Rare Disease Portfolio Through Viela Bio Purchase
Horizon Therapeutics plans to expand its rare disease therapy portfolio through the purchase of Viela Bio in a deal valued at more than $3 billion.
Through the acquisition, Horizon will gain access to Viela’s Uplinza (inebilizumab-cdon), a monoclonal antibody approved by the FDA last year for treating neuromyelitis optica spectrum disorder, an autoimmune disease that can lead to loss of vision and paralysis.
Horizon will also get Viela’s Tepezza (teprotumumab-trbw) for treating thyroid eye disease and Krystexxa (pegloticase) for treating chronic gout. Both received the FDA’s approval in 2020.
The transaction is expected to close by the end of this quarter.